Zacks: Brokerages Anticipate Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Will Announce Earnings of -$2.26 Per Share

Brokerages expect Reata Pharmaceuticals, Inc. (NASDAQ:RETAGet Rating) to report earnings per share of ($2.26) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Reata Pharmaceuticals’ earnings. Reata Pharmaceuticals reported earnings per share of ($1.86) during the same quarter last year, which indicates a negative year-over-year growth rate of 21.5%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($9.29) per share for the current fiscal year, with EPS estimates ranging from ($10.34) to ($8.04). For the next financial year, analysts forecast that the business will post earnings of ($7.56) per share, with EPS estimates ranging from ($8.26) to ($6.17). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETAGet Rating) last announced its earnings results on Monday, February 28th. The company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($2.31) by ($0.04). Reata Pharmaceuticals had a negative net margin of 2,588.22% and a negative return on equity of 105.72%. The business had revenue of $0.93 million for the quarter, compared to the consensus estimate of $1.76 million. During the same quarter in the previous year, the company earned ($1.90) EPS.

A number of analysts recently weighed in on the company. The Goldman Sachs Group upgraded Reata Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $34.00 to $91.00 in a report on Thursday, March 24th. StockNews.com started coverage on shares of Reata Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $115.14.

RETA stock opened at $25.38 on Friday. The business’s 50-day moving average price is $32.50 and its two-hundred day moving average price is $47.56. Reata Pharmaceuticals has a 1-year low of $22.71 and a 1-year high of $153.41.

A number of large investors have recently added to or reduced their stakes in RETA. FourThought Financial LLC boosted its stake in Reata Pharmaceuticals by 58.0% during the third quarter. FourThought Financial LLC now owns 583 shares of the company’s stock worth $58,000 after buying an additional 214 shares during the period. Macquarie Group Ltd. raised its stake in Reata Pharmaceuticals by 60.1% in the 3rd quarter. Macquarie Group Ltd. now owns 594 shares of the company’s stock valued at $60,000 after purchasing an additional 223 shares during the last quarter. O Shaughnessy Asset Management LLC increased its stake in shares of Reata Pharmaceuticals by 6,360.0% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 646 shares of the company’s stock valued at $65,000 after acquiring an additional 636 shares during the last quarter. First Mercantile Trust Co. increased its stake in shares of Reata Pharmaceuticals by 20.6% during the 3rd quarter. First Mercantile Trust Co. now owns 721 shares of the company’s stock valued at $73,000 after acquiring an additional 123 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Reata Pharmaceuticals in the 4th quarter worth approximately $97,000. 73.55% of the stock is currently owned by institutional investors.

Reata Pharmaceuticals Company Profile (Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

See Also

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.